NCT02057640View on ClinicalTrials.gov

MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 22, 2014

Primary Completion Date

May 15, 2018

Study Completion Date

May 15, 2018

Conditions
Multiple MyelomaKahler DiseasePlasma-Cell MyelomaMyelomatosis
Interventions
DRUG

Panobinostat

20mg, on day 1, 3, 5, 15, 17, 19, 28

DRUG

Dexamethasone

20mg, on day 1, 2, 8, 9, 15, 16, 28

DRUG

MLN9708

4mg on day 1, 8, 15, 28

Trial Locations (2)

44106

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Jason Valent

OTHER

NCT02057640 - MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma | Biotech Hunter | Biotech Hunter